These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18516354)

  • 21. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyslipidaemia in rural Australia: prevalence, awareness, and adherence to treatment guidelines in the Greater Green Triangle Risk Factor Study.
    Janus ED; Tideman PA; Dunbar JA; Kilkkinen A; Bunker SJ; Philpot B; Tirimacco R; Mc Namara K; Heistaro S; Laatikainen T
    Med J Aust; 2010 Feb; 192(3):127-32. PubMed ID: 20121678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
    Tan NC; Goh CC; Goh SC; Koh YL; Koh KH
    J Clin Pharm Ther; 2016 Dec; 41(6):677-683. PubMed ID: 27641514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
    Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
    Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA).
    Klug E; Raal FJ; Marais AD; Smuts CM; Schamroth C; Jankelow D; Blom DJ; Webb DA
    S Afr Med J; 2018 Oct; 108(11b):973-1000. PubMed ID: 30421699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia.
    Raal F; Schamroth C; Blom D; Marx J; Rajput M; Haus M; Hussain R; Cassim F; Nortjé M; Vandehoven G; Temmerman AM
    Cardiovasc J Afr; 2011; 22(5):234-40. PubMed ID: 21922121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
    Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
    Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.
    Halcox JP; Tubach F; Lopez-Garcia E; De Backer G; Borghi C; Dallongeville J; Guallar E; Medina J; Perk J; Sazova O; Sweet S; Roy C; Banegas JR; Rodriguez-Artalejo F
    PLoS One; 2015; 10(2):e0115270. PubMed ID: 25692692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.
    Arnold SV; Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Alam S; Mues KE; Bhatt DL; Kosiborod M;
    J Am Heart Assoc; 2021 Aug; 10(16):e020893. PubMed ID: 34369165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
    Corcillo A; Pivin E; Lalubin F; Pitteloud N; Burnier M; Zanchi A
    Swiss Med Wkly; 2017; 147():w14459. PubMed ID: 28695552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
    Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
    Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
    Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care.
    Farahani P; Levine M; Gaebel K; LeLorier J; Perrault S; Gillis J; Soon J
    Clin Invest Med; 2007; 30(2):E63-9. PubMed ID: 17716543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL)].
    Föger B; Patsch JR
    Wien Klin Wochenschr; 2011 Jan; 123(1-2):21-7. PubMed ID: 21165704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
    Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
    Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting.
    Lacy CR; Suh DC; Barone JA; Bueno M; Moylan D; Swartz C; Kudipudi RV; Kostis JB
    Arch Intern Med; 2002 Feb; 162(4):468-73. PubMed ID: 11863482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.